🫁 ASCO 2026 was a powerful reminder of how fast lung cancer care is changing. From targeted therapy and antibody-drug conjugates to immunotherapy combinations, screening innovation, patient advocacy, and resistance prevention, lung cancer had a major presence throughout the meeting. This year’s conversations touched nearly every part of thoracic oncology: 🔬 Long-term outcomes in ALK-positive NSCLC 🎯 New first-line targeted options for EGFR exon 20 insertion NSCLC 🚀 Sac-TMT plus pembrolizumab in PD-L1-positive advanced NSCLC 🧬 RET-positive early lung cancer and the growing importance of molecular testing 💉 DLL3-targeted ADC data in small cell lung cancer 🌍 Lung cancer in never-smokers and global innovation in thoracic oncology 🧪 Early detection, screening deserts, and blood-based approaches 🤝 Patient advocacy, clinical partnerships, and the human stories behind the data What stood out most was not only the science, but the momentum. Lung cancer care is becoming more precise, more global, and more patient-centered. To capture some of the most interesting conversations from the meeting, we selected 20 lung cancer posts from ASCO 2026 not to miss. These posts highlight the studies, reflections, and moments that shaped one of the most important oncology meetings of the year. Read more on @OncoDailyLung @DNABARCODE @acmoorephd @Chris_PouliosMD @Jbauml @tnewsomdavis